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Medicine and Surgery, Federico II University. PAbstract Background and aims: Atherogenesis and endothelial dysfunction contribute to car-
diovascular risk and vitamin D has been implemented in endothelial repair. This systematic re-
view, meta-analysis and meta-regression aims to establish the effect of vitamin D
supplementation on endothelial function.
Methods and Results: To conduct the systematic review we searched the Cochrane Library of
Controlled Trials, PubMed, ProQuest and EMBASE for randomized controlled trials that investi-
gated the effects of vitamin D supplementation on flow-mediated dilation (FMD%), pulse wave
velocity (PWV), and central augmentation index (AIx). Meta-analysis was based on a random ef-
fects model and inverse-variance methods to calculate either mean difference (MD) or standard-
ized mean difference (SMD) as effects sizes. This was followed by meta-regression investigating
the effect of baseline vitamin D concentrations, vitamin D dosing and study duration. Risk of bias
was assessed using the JADAD scale and funnel plots.
We identified 1056 studies of which 26 studies met inclusion criteria for quantitative analysis.
Forty-two percent of the 2808 participants had either deficient or insufficient levels of vitamin D.
FMD% (MD 1.17% (95% CI 0.20, 2.54), p Z 0.095), PWV (SMD 0.09 m/s (95% CI 0.24, 0.07),
p Z 0.275) and AIx (SMD 0.05% (95% CI 0.1, 0.19), p Z 0.52) showed no improvement with
vitamin D supplementation. Sub-analysis and meta-regression revealed a tendency for AIx and
FMD% to increase as weekly vitamin doses increased; no other significant relationships were
identified.
Conclusions: Vitamin D supplementation showed no improvement in endothelial function. More
evidence is required before recommendations for management of endothelial dysfunction can be
made.
ª 2019 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the
Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Feder-
ico II University. Published by Elsevier B.V. All rights reserved.cience, School of Science and
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Cardiovascular disease (CVD) is the leading cause of death
globally, with an estimated 17.7 million deaths from the
disease worldwide in 2015 [1]. Global CVD burden is
estimated to increase to USD 1044 billion by 2030 [2].
Atherosclerosis is indicated as the primary cause of CVDtherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical
d.
1262 N.L. Pincombe et al.and the critical step in CVD commencement and progres-
sion with endothelial dysfunction (ED) and associated loss
of endothelial integrity presenting as a precursor stage of
atherosclerosis [3].
The vascular endothelium can be classified as a complex
paracrine and endocrine organ that produces vasodilatory
and vasoconstricting factors, most importantly, nitric oxide
(NO) [4]. Endothelial dysfunction encompasses dysregu-
lation of mechanistic processes facilitating vasodilatory
function of the endothelium, and the actual functionality
of the endothelium itself [5]. This broadens the assess-
ments of ED beyond the simple scope of the physical
functionality of the endothelial wall and expands the
scope to include platelet aggregation and adhesion,
vascular inflammation and thrombosis management [5].
Endothelial dysfunction is characterised by a decrease in
bioavailable NO leading to a reduction in endothelial
vasodilation in response to vasodilatory stimuli [6].
Endothelial dysfunction is the initial, and reversible step in
atherogenesis development, and is used as a primary tool
for clinical identification of the presence and extent of
atherosclerosis by measuring endothelial vasoreactivity
[5,7]. Measurement of ED is used as a predictor of CVD
mortality risk [8]. Endothelial dysfunction is measured
through both invasive and non-invasive methods, the most
common being central augmentation index percentage
(AIx), pulse wave velocity (PWV), and artery flow-
mediated dilation (FMD%), the latter considered as the
gold standard of ED assessment [5].
Vitamin D is a secosteroid hormone most commonly
associated with calcium regulation regarding bone
remodelling [9]. Lower serum concentrations of vitamin D
have been associated with increased risk of CVD patho-
genesis, including increased risk of hypertension,
decreased myocyte contractility and increased arterial
calcification [10]. Vitamin D receptors are expressed in
numerous tissues, and due to their expression in cardio-
vascular tissues, focus has shifted to vitamin D effects on
CVD risk factors, including endothelial function [9]. Spec-
ulation exists for the mechanisms for which vitamin D af-
fects endothelial function through NO regulation. One
study showed that calcitriol, the hormonally active
metabolite of vitamin D, increases monocyte differentiation
into myeloid angiogenic cells and augments their angio-
genic capacity for endothelial repair, as well as increasing
endothelial NO synthase expression, increasing endothelial
function [11]. Several RCTs have reported equivocal results
regarding the effects of vitamin D supplementation on
arterial stiffness, an important measure of CVD risk,
continuing the trend of conjecture regarding RCT results of
vitamin D and CVD outcomes [9,10,12e16]. The positive
effects of vitamin D on reducing CVD risk factors remain
questionable due to RCT results being obtained from pop-
ulations without hypovitaminosis D. This, and the short
duration of the RCTs fails to confirm observational study
results which show a positive correlation between vitamin
D concentrations and CVD risk factor reduction [13].
Given the expression of vitamin D receptors throughout
cardiac tissues, it is entirely conceivable that vitamin Dsupplementation may improve cardiovascular outcomes,
with proposed mechanisms including decreasing the ef-
fects of chronic inflammation and decreased vascular
smooth muscle cell proliferation [17,18].
This systematic review with meta-analysis and meta-
regression aims to summarise the currently available evi-
dence from RCTs investigating supplemental vitamin D
effects on endothelial function in both healthy and clinical
populations. The intent is to draw conclusions as to
whether supplemental vitamin D can be recommended for
prevention of establishment or progression of ED.
Added value to previous meta-analyses on the same topic
Previous systematic reviews and meta-analyses
[9,12,19e23] have reported on the effects of vitamin D
supplementation and markers of endothelial function;
however, not all included FMD%, PWV and AIx as a primary
outcome measure and only one provided analyses for all
three [23]. In addition, a number of new trials have
recently been published and are included in the present




A systematic search was conducted to identify potential
studies using the following electronic databases: the
Cochrane Library of Controlled Trials, PubMed, ProQuest
and EMBASE until 31st May 2019. Search criteria included
numerous terms, both free text and MeSH regarding
atherosclerosis, vitamin D2 and vitamin D3, endothelial
function, endothelial dysfunction and terms titling
methods for assessing endothelial function. Systematic
reviews, meta-analyses, and study bibliographies were
reviewed for additional studies. Three reviewers (NP, MP,
GD) conducted the search and full article eligibility review.
Study selection
The following criteria were applied for study identification
and selection (1) Randomized, double-blinded, placebo
controlled trials; (2) studies conducted in all age groups
with no additional exclusion criteria applied for sex, health
status or CVD risk factors; (3) vitamin D2 or D3 as primary
intervention (dose, administration method or route of
vitamin D2 or D3 administration, or inclusion of other
secondary interventions were not a basis for study exclu-
sion). Studies using the vitamin D receptor activator Par-
icalcitol were excluded.
Data extraction and outcome measures
Data extraction was completed by three reviewers (NP, MP,
GD). Primary outcomes measured were limited to endo-
thelial function test measurements conducted via FMD%,
PWV and AIx. Studies reporting FMD values were included
Vitamin D supplementation on endothelial function 1263if the measurement was reported as relative FMD per-
centage (FMD%) or as absolute FMD (measured in cm, mm
or mm) in the brachial artery. Where FMD was reported as
both absolute FMD and FMD%, only data from the FMD%
was extracted for analysis. Studies selected presented
numerous PWV and AIx measurements and were
included; studies that did not state PWV method were
excluded. Units of measure reported for PWV outcomes
were converted to m/s.
Data synthesis
Individual meta-analyses were completed for continuous
data utilizing the change in mean and standard deviation
(SD) values for the study populations. Where the change in
mean and SD was not reported, the pre-intervention mean
was subtracted from the post-intervention mean, and the
change SD was calculated utilizing study group participant
numbers in conjunction with group p-values or 95% CI.
Where exact p-values or 95% CI were not available the SD
of the mean difference was imputed using the formula,
SD Z square root [(SDpre-treatment)2 þ (SDpost-treat-
ment)2(2rSDpre-treatment x SDpost-treatment)] [24], assuming a
correlation coefficient (r) Z 0.5, which is considered a
conservative estimate. Where the standard error of the
mean (SEM) was given instead of the SD, this value was
converted to SD [24]. Data from studies that reported
median and interquartile range (IQR 1st and 3rd quarter)
was converted to mean and SD using the method
described in Wan et al. [25]. Studies that reported data as
median and 50% IQR had data converted to mean and
estimated SD assuming the value given was approximately
1.35 standard deviations. Mean differences (MD) in
conjunction with random effects inverse variance were
applied to pooled data for FMD% analysis. Standardized
Mean Differences (SMD) were utilized in conjunction with
a random effects inverse variance to allow for comparison
between differing effects sizes and methods of measure-
ment of the outcome between selected studies, as was the
case when conducting analyses for both PWV and AIx
pooled data groups. Using current guidelines, SMD values
of 0.2, 0.5 and 0.8 signify small, medium and large effects
sizes, respectively [26]. Placebo group numbers were
evenly divided amongst intervention study groups in
selected studies that presented data for more than one
intervention group. Forest plots were generated to provide
visual representation of vitamin D effects on endothelial
function. A 95% CI was selected to report changes in
measured outcomes. Sensitivity analysis was conducted
using the leave-one-out method for overall assessment of
the intervention effect. Where studies did not report data
suitable for pooling, a descriptive analysis was included.
Meta-regression analysis was performed (NK) to investi-
gate the heterogeneity of results using baseline vitamin D
concentrations, weekly dose of vitamin D supplement and
duration of study as covariates with a 5% level of signifi-
cance and 95% confidence intervals [27]. All analyses were
carried out and all figures were produced in Comprehen-
sive Meta-Analysis (CMA) V3 (Biostat Inc., NJ, USA).Heterogeneity and publication bias
Heterogeneity between included studies was calculated
using CMA V3; the I2 test was utilized for consistency
appraisal between studies. Values < 25% show low risk of
heterogeneity, whereas >75% shows high risk of hetero-
geneity. Values that fall between 25 and 75% show mod-
erate risk of heterogeneity [24]. These values together with
assessment of funnel plots and Egger’s regression test
were used to evaluate overall heterogeneity and assess risk
of publication bias [28].
Study quality
Study quality was assessed using the JADAD scale [29].
The maximum score possible is 5; with a score of 3
indicating high risk of bias, while a score of >3 indicated a
low risk of bias. Study quality was performed by two as-
sessors (NP, GD).
Results
Using allocated search criteria, the search of the four
selected databases identified 1056 manuscripts. After
removal of duplicates, 59 full-text articles were assessed
for eligibility. After screening, a total of 32 full-text papers
remained for inclusion in the qualitative analysis, of which
26 were eligible for inclusion in the meta-analysis as per
PRISMA flow diagram (Fig. 1).
Study characteristics
Thirty-two studies were included in the qualitative anal-
ysis with 26 suitable for inclusion in the meta-analysis.
Reasons for exclusion of the six studies from the meta-
analysis are detailed in Supplementary Table 1. The total
number of participants analyzed for the specified out-
comes from the 26 studies [4,10,14e16,30e50] included in
the meta-analysis was 2808. There was a diversity of
participants in the studies, with the inclusion of both
healthy and clinical populations. Of the 26 studies, six
[4,14,30,42,45,48] provided a total of 327 participants
diagnosed with Type 2 Diabetes Mellitus (T2DM) with 55
of these participants identified as being diagnosed with
T2DM and non-alcoholic fatty liver disease (NAFLD) [30].
Four studies [15,38,40,50] provided a total of 273 partici-
pants diagnosed with various stages of Chronic Kidney
Disease (CKD). Remaining studies of clinical populations
included participants with increased risk of diabetes,
polycystic ovarian syndrome (PCOS), human immunode-
ficiency virus (HIV), peripheral arterial disease (PAD),
chronic fatigue, and CVD. Age group amongst participants
ranged from 22.4 to 72.9 (average age 54.6  14.8). Sex
distribution was primarily male. Of the 26 included
studies, 8 studies included participants with deficient
(<12.5 ng/ml), 11 studies with inadequate (<20 ng/ml) and
7 studies with adequate (20 ng/ml) baseline vitamin D
levels for optimal overall health as per National Institutes
of Health recommendations e 58% of participants were
Figure 1 PRISMA flow diagram.
1264 N.L. Pincombe et al.considered to have adequate vitamin D levels. Character-
istics of all included studies are detailed in Table 1.
Intervention details
Intervention duration ranged from four to 57 weeks with
most studies using a 16-week intervention period. Vitamin
D supplementation dosing ranged from 892 IU/d to
7142 IU/d, with the higher doses due to singular large
dosing either at the start of the study period [44,45,47], or
large doses at interval periods longer than daily dosing
[10,15,16,32,33,36e38,43,49,50]. Accounting for single
dose effect over the intervention period most studies used
between 2000 IU/d to 5000 IU/d and all studies supple-
mented vitamin D orally. All studies except for two[10,45,51] used vitamin D3, with one study using both
vitamin D2 and D3 for the intervention [32]. In a number
of studies, participants were using multiple pharmaceu-
tical treatments in addition to either vitamin D or placebo.
One study [33] included dosing of metformin with either
4000 IU of vitamin D plus 1500 mg of metformin, or pla-
cebo plus 1500 mg of metformin. One study included use
of HIV medications [37] with either vitamin D or placebo.
One study included 200 mg/d of calcium [42] with either
vitamin D or placebo. Dosing intervals ranged from daily
dosing to once every three months. To test endothelial
function several methods were used across all studies,
with the most common being FMD% [10,15,30,34,35,
37,45,47e49], PWV [15,16,31e34,36,38,40e43,50] and AIx
[4,14,31,33,34,36,38,40,42e44,46,47,49].
Table 1 Characteristics of studies included in the meta-analysis and -regression.
First Author Study
Design





















T2DM with NAFLD 55 26 2000 IU/d (D3) 29 24 16.06  9.56 (C)
19.26  9.48 (VD)










T2DM 32 19 1000 IU/d (D3) 13 52 11.7  6.5 (C)






Healthy 40 22 3000 IU/d (D3) 18 16 12.8  4 (C)
12.4  4.4 (VD)
No effect on PWV





T2DM 61 31 2000e4000 IU/d (D3) 30 16 17  11 (C)
18  7 (VD)












52 16 18.32  10.52 (C)
19.44  9.88 (VD2)






PCOS 32 15 120,000 IU/m (D3) 17 24 6.8  2.46 (C)
7.7  6.05 (VD)
No effect on PWV








75 (PWV & Alx)
55 (FMD)
38 (PWV & Alx)
2500 IU/d (D3) 54 (FMD)
37 (PWV & Alx)
16 32.3  10.5 (C)
30.3  10.7 (VD)
No effect on FMD
No effect on PWV





Overweight 45 22 60,000 IU/m (D3) 23 16 15.28  1.2 (C)






CKD 117 58 300,000 IU at baseline
and 8 w (D3)
59 16 13.21  4.78 (C)











3000 IU/d (D3) 57
55
20 23  12 (C)
23  9 (VD)
No effect on PWV





CKD 87 57 15,000 IU/w (D3) 30 21 29.4  12.7 (C)






HIV 45 30 4000 IU/d (D3) 15 12 6.2 (IQR 3.7e9.8) (C)
9 (IQR 7.1e13.1) (VD)









40,000 IU/w (D3) 16(PWV)
14 (Alx)
8 13.2 (IQR 9.4e17.1) (C)
9.5 (IQR 6.9e16.6) (VD)
No effect on PWV





Overweight/obese 130 65 100,000 IU/m (D3) 65 12 6.6  2 (C)












3000 IU/d (D3) 19
22
24 11.2 (IQR 8e27.6) (C);
11.2 (IQR 8e19.2) (VD)






Hypertension 153 81 2800 IU/d (D3) 72 8 20.4  5.7 (C)
22.0  5.5 (VD)











17 16 15.9  3.9 (C)
14  3.9 (VD-18,000)
15.9  3.7 (VD-60,000)






T2DM 45 24 2000 IU/d (D3) 21 24 10.7  2.6 (C)
12.3  3.0 (VD)
No effect on PWV
No effect on AIx











Table 1 (continued )
First Author Study
Design























517 256 200,000 (D3) initially,
then 100,000 IU/m
261 57 25.24  9.84 (C)
24.84  9.88 (VD)
No effect on PWV
No effect on Alx







PAD 62 31 100,000 IU - single
dose (D3)
31 4 17  5.5 (C)
16.3  6.7 (VD)






T2DM 34 17 100,000 IU - single
dose (D2)
17 8 14.56  3.4 (C)











101 52 20 e all groups No effect on PWV







Healthy 50 25 100,000 IU - single
dose (D3)
25 8 10.8  6 (C)
10.8  5.2 (VD)
No effect on FMD
No effect on PWV






Chronic Fatigue 50 25 100,000 IU/2
months (D3)
25 24 19.2  8 (C)
17.6  6 (VD)
No effect on FMD





T2DM 100 50 5000 IU/d (D3) 50 12 21.9  4.1 (C)
21.1  4.4 (VD)
No effect on FMD
No effect on PWV
Alx: augmentation index, C: control/placebo group; CKD: chronic kidney disease, d: day; DB: double blind, FMD: flow-mediated dilation, HIV: human immunodeficiency virus, HT: hypertension; IQR:
interquartile range; m: month; NAFLD: non-alcoholic fatty liver disease, PAD: peripheral artery disease, PCOS: polycystic ovarian syndrome, PG: parallel group, P: prospective, PWV: pulse wave







Vitamin D supplementation on endothelial function 1267Outcome measures
Flow-mediated dilation
Ten studies assessed FMD% as either a primary or sec-
ondary outcome and included a total of 689 participants
[10,15,30,34,35,37,45,47e49]. Vitamin D supplementation
did not improve FMD% with MD 1.17% (95% CI 0.20,
2.54), p Z 0.095 (Fig. 2). Three additional studies [52e54]
reported on FMD%, however, data did not allow for
pooling. All three of these studies reported no change in
FMD% with vitamin D supplementation. Sensitivity
analysis for FMD% indicated that the studies of Kumar
(2017) [15] and Harris (2011) [35] impacted the size and
significance of the result. Upon removal of these studies,
MD was reduced to 0.67% (95% CI 0.55, 1.88), p Z 0.28
and 0.92% (95% CI 0.66, 2.49), p Z 0.25, respectively
(Supplementary Table 2).
Pulse wave velocity
Seventeen studies assessed PWV as either a primary or
secondary outcome [15,16,31e34,36,38,40e43,50] and
included a total of 1981 participants. Vitamin D supple-
mentation did not improve PWV with SMD 0.09 m/s
(95% CI 0.24, 0.07), p Z 0.275 (Fig. 3). An additional four
studies [51,52,55,56] reported on PWV (data did not allow
for pooling) and showed no change in PWV with Vitamin
D supplementation. Leave-one-out sensitivity analysis for
PWV did not indicate that any study overly impacted the
results (Supplementary Table 3).
Augmentation index percentage
Fifteen studies assessed AIx as either a primary or secondary
outcome AIx [4,14,31,33,34,36,38,40,42e44,46,47,49] and
included a total of 1569 participants. Vitamin D supple-
mentation did not improve AIx with SMD 0.05% (95% CI0.1,
0.19), p Z 0.52 (Fig. 4). An additional study [55] reported on
AIx (data did not allow for pooling) and reported no changeFigure 2 FMD%: Vitamin D suin AIx with vitamin D supplementation. Leave-one-out
sensitivity analysis for AIx did not indicate that any study
overly impacted the results (Supplementary Table 4).
Sub-analyses of vitamin D supplementation effect on
FMD%, PWV and AIx
Sub-analyses were conducted for FMD%, PWV and AIx on
the effect of baseline vitamin D levels (deficient, inade-
quate or adequate), vitamin D supplementation (daily,
weekly, monthly or 2-monthly), the amount of vitamin D
administered (<20,000 IU/week or >20,000 IU/week), and
in populations with T2DM and CKD (Supplementary
Figures 1 to 12).
Baseline vitamin D levels seemed to improve FMD% in
those participants with inadequate vitamin D levels with
MD 1.8% (95% CI 0.06, 3.68), p Z 0.057. In participants
with deficient or inadequate baseline vitamin D levels,
PWV showed some improvement in vitamin D deficient
participants with SMD 0.29 m/s (95% CI 0.01, 0.6),
p Z 0.06 and was significantly decreased in participants
with inadequate vitamin D levels, favouring the placebo
group, with 0.38 m/s (95% CI 0.09, 2.59), p Z 0.01,
respectively. AIx was not affected by baseline vitamin D
levels (Supplementary Figures 1e3).
The timing of vitamin D supplementation did not signif-
icantly improve FMD%, PWV or AIx when supplemented
daily, weekly, monthly or 2-monthly (Supplementary
Figures 4e6).
Vitamin D dosage of <20,000 IU/week vs. >20,000 IU/
week did not significantly affect FMD% or PWV; however,
AIx showed a significant improvement when doses of
>20,000 IU/week were administered with SMD 0.13% (95%
CI 0.015, 0.25), p Z 0.03 (Supplementary Figures 7e9).
Type 2 Diabetes e Pooled data for FMD%, PWV and Alx
on Vitamin D supplementation in populations with T2DM
did not demonstrate a significant improvement in any
measure (Supplementary Figures 10 and 12). Onepplementation vs placebo.
Figure 3 PWV: Vitamin D supplementation vs placebo.
Figure 4 AIx: Vitamin D supplementation vs placebo.
1268 N.L. Pincombe et al.additional study in a T2DM population [54], not included
in the pooled analysis also failed to find any significant
improvement.
Chronic Kidney Disease e Only one study [15] included
in the review reported FMD% in a population with CKD;
vitamin D supplementation improved FMD% with MD5.49% (95% CI 4.35, 6.63), p Z 0.00. Subgroup analyses for
PWV (4 RCTs) and Alx (2 RCTs) failed to indicate any sig-
nificant improvement (Supplementary Figures 10 and 12).
Two additional studies [51,56] in CKD patients, not
included in the pooled analysis, also failed to demonstrate
any significant improvements.
Vitamin D supplementation on endothelial function 1269Meta-regression for covariates
The covariates baseline vitamin D concentration, weekly
dose of vitamin D supplement and study duration were
investigated for FMD%, PWV and AIx. There was a ten-
dency for the mean difference of FMD% to increase as
weekly dose of vitamin D supplementation increased
(p Z 0.05). No other significant relationships were found
(Supplementary Figures 13e21).
Study quality assessment
The median JADAD score was 5 out of a maximum score of
5 (Supplementary Table 5). Most studies scored 5; how-
ever, a few studies lost points due to either not describing
the method of blinding or randomization.
Heterogeneity and publication bias
Most analyses demonstrated moderate to high heteroge-
neity with I2 Z 90.38% for FMD%, I2 Z 58.23% for PWV and
I2 Z 38.07% for AIx. Egger funnel plots showed little evi-
dence of publication bias with an intercept of 4.05 (95%
CI 8.76, 0.67), p Z 0.083 for FMD%, 0.16 (95% CI 1.87,
1.55), p Z 0.85 for PWV and 0.93 (95% CI 2.47, 0.61),
p Z 0.217 for AIx (Supplementary Figures 22e24).
Discussion
This systematic review with meta-analysis and meta-
regression found little evidence to support the use of
vitamin D supplementation to improve endothelial func-
tion. Pooled data failed to demonstrate any statistically
significant improvement in FMD%, PWV and AIx, all of
which are considered markers of endothelial function.
These results are consistent with previous analyses on
vitamin D supplementation and endothelial function
[9,12,21,23] and another analysis that has identified a lack
of positive effects for treatment of hypertension with
vitamin D [57]. Our results and those of these previous
analyses contrast with a recent analysis [19], which
demonstrated a significant improvement in FMD%. This
analysis differed from ours by conducting the assessment
of vitamin D supplementation on FMD% with studies that
did not meet our inclusion criteria and included studies
that conducted assessment of supplemental vitamin D and
vitamin D analogues [58]. Our analysis included the study
by Sluyter (2017) [43] which recruited the largest number
of participants to date investigating the effects of vitamin
D on central and brachial blood pressure parameters and
failed to find any significant effect of vitamin D supple-
mentation on PWV and AIx. However, a subgroup analysis
in participants with vitamin D deficiency indicated sig-
nificant improvements in PWV and Alx [43].
Results amongst pooled study data are conflicting and
possibly due to heterogeneity of vitamin D dosing, dosing
schedules, baseline concentrations, duration of interven-
tion, study power [44,59,60] and possible confounding
factors which included sunlight exposure, diet, medica-
tions and unverified additional supplementation [16,42].Choice of vitamin D type may also affect RCT results, as
new evidence indicates that vitamin D3 is more biologi-
cally active than vitamin D2 [61,62]. However, only three
out of 26 studies [10,32,45] included in this meta-analysis
used vitamin D2 supplementation. Several studies
included supplemental or pharmacological interventions
as a part of the selected population group, including cal-
cium [42], HIV medications [37] and metformin [33].
Vitamin D receptor genetic variation [63], body mass index
and disease-related biases for vitamin D metabolism may
have also influenced results that vitamin D supplementa-
tion may have a positive effect on populations with T2DM
[14,45] and CKD [15,40,50,64]. This was not confirmed by
recent systematic reviews [22,65]. One study [66] suggest
that higher risk of CVD due to hypovitaminosis may be due
to a phenotypical trait over one or several specific CVD risk
factors, with additional sex-related differences such as
hormonal factors, as indicated with women appearing to
have an increased risk of a number of CVD risk factors in
comparison to men. Standardization of populations for
comparison whilst accounting for external factors
including environmental, smoking and dietary intake
variation increase the challenge for identification of actual
long-term effects of vitamin D supplementation.
Individually, only eight trials included in this systematic
review reported a significant improvement in FMD%, PWV
or AIx [14e16,32,35,40,45,50], when the intervention
groups were compared to the placebo groups. Two of the
studies [16,35] were conducted in populations of over-
weight African-Americans, one of these studies only
included participants who were vitamin D deficient [16].
Two of the studies were conducted in populations with
T2DM or at risk of T2DM [14,45], one [32] in a population
of participants at an increased risk of T2DM. Three studies
were conducted in CKD participants [15,40,50].
Our sub-analyses investigated the effects of vitamin D
supplementation considering participants’ baseline
vitamin D levels, dosing schedules, dose of vitamin D
administered, and chronic diseases. Participants with
deficient or inadequate baseline vitamin D levels tended to
show some improvements in PWV and FMD%, respec-
tively; conflictingly, PWV was significantly decreased in
those with inadequate levels of vitamin D at baseline.
Dosing schedules did not improve FMD%, PWV and AIx;
however, higher doses of vitamin D significantly improved
the AIx especially in participants with deficient or inade-
quate baseline vitamin D levels. Sub-analysis of T2DM and
CKD participants showed no improvements in endothelial
function with only one study of CKD participants [15]
finding a significant increase in FMD%. Populations with
CKD are commonly vitamin D deficient [51,67] somewhat
due to a reduction in vitamin D receptors and receptor
resistance [68e71], impaired vitamin D tubular resorption
[72] and reduced hepatic and renal synthesis of 1,25-
dihydroxycholecalciferol due to decreased hepatic
CYP450 enzyme expression and reduced renal 1a-hy-
droxylase [73]. The effectiveness of higher doses of vitamin
D supplementation to improve FMD% may be due to a
reduction in renal hyperparathyroidism through vitamin D
1270 N.L. Pincombe et al.induced suppression of elevated intact parathyroid hor-
mone [15,74] by increasing catabolism of vitamin D to 1,25
hydroxyvitamin D [75]. Additionally, vitamin D supple-
mentation could increase control of hemodynamic factors
through reduction of renin-angiotensin-aldosterone sys-
tem activity reducing the effects of hypertension on CKD
[76e78]. Vitamin D supplementation may improve car-
diovascular risk factors in non-diabetic patients in early
stages of CKD.
Our meta-regression analyses found no significant re-
lationships for the covariates baseline vitamin D levels,
weekly dose of vitamin D or study duration.
Further research is still required to understand the
mechanistic effects of vitamin D and other endogenous
compounds for prevention of atherosclerosis. Future
research in populations that commonly use several sup-
plements, including vitamin D and calcium, may help to
determine if combination supplementation can improve
endothelial function and reduce the risk of atherosclerosis,
such as in post-menopausal females supplementing with
calcium to decrease osteoporosis risk. Additionally, anal-
ysis of whether nutritional or supplemental sources
decrease risk of atherosclerosis would be of benefit.
There are a number of strengths to this paper. No study
intervention dose fell below minimum Australian recom-
mended dosing requirements for study participants, being
200 IU/day for populations aged 19e50 years old, 400 IU/day
for populations aged 50e70 years old, and 600 IU/day for
populations aged 70 years or older [79]. The meta-analysis
utilized data only provided by trials that were designed as
placebo-controlled, randomized, double-blind trials. Strin-
gent selection criteria focused specifically on vitamin D2 and
D3, excluding vitamin D analogues like the commonly pre-
scribed vitamin D receptor activiator Paricalcitol for CKD. The
primary rationale for this was to investigate recommenda-
tions for over-the-counter options for the consumer to assist
with improving endothelial function.
There were several limitations that need to be high-
lighted for this systematic review and the meta-analysis
and meta-regression. The shortest intervention time was
four weeks [44] which may be less than the estimated
required time period for vitamin D repletion to occur due
to the accepted half-life of vitamin D being eight weeks,
and possible variations between half-lives of vitamin D2
and D3 [63]. Most studies used a 16-week intervention
period which could be argued as still being too short to
observe vitamin D facilitated changes on surrogate
markers of arterial stiffness. Seven studies ran over 20e24
weeks, two studies had a study duration of 1 year, and only
one study was conducted for longer than 12 months [43].
Our meta-regression analyses did not confirm any im-
provements in endothelial function with increased study
duration. FMD%, PWV or AIx were not the primary
outcome measures in some studies, hence statistical
power may have affected the results of these studies. Only
studies that measured FMD%, PWV and AIx were included;
however, several other indices are markers of endothelial
function and hence the results need to be interpreted with
this context.In conclusion, this meta-analysis and meta-regression
suggests that vitamin D supplementation has no signifi-
cant effect for improving endothelial dysfunction,
although there is a tendency to improve FMD%. The cur-
rent evidence is conclusive enough to suggest that sup-
plementation or pharmacological prescription of vitamin
D is not warranted for improving endothelial dysfunction.
It is still unclear whether vitamin D supplementation is
required for those population groups that require reple-
tion. There is some evidence that vitamin D supplemen-
tation may be beneficial for populations with CKD, or
overweight populations.Conflicts of interest
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